ArticleGut2017
T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes.
Article in Gut, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04622423 (Advanced Immune Gene and Cell Therapies for Liver Metastases), which is not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Advanced Immune Gene and Cell Therapies for Liver Metastases
Who cites it
35 citing papers in PubMed, 80 citations in OpenAlex.
- Mechanism of neoantigen generation and advances in neoantigen-based immunotherapies in colorectal cancer.Medical oncology (Northwood, London, England) · 2026Review
- Cancer Stem Cells Connecting to Immunotherapy: Key Insights, Challenges, and Potential Treatment Opportunities.Cancers · 2025Review
- New insights on anti-tumor immunity of CD8Journal of translational medicine · 2025Review
- The integrative genomic and functional immunological analyses of colorectal cancer initiating cells to modulate stemness properties and the susceptibility to immune responses.Journal of translational medicine · 2025Article
- Cancer-associated foam cells hamper protective T cell immunity and favor tumor progression in human colon carcinogenesis.Journal for immunotherapy of cancer · 2024Article
- Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma.Blood advances · 2024Article
- Harnessing the power of AI in precision medicine: NGS-based therapeutic insights for colorectal cancer cohort.Frontiers in oncology · 2024Article
- Cancer Stem Cells in Colorectal Cancer: Implications for Targeted Immunotherapies.Journal of gastrointestinal cancer · 2023Review
- Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma.Cancer research · 2023Article
- Macrophage's role in solid tumors: two edges of a sword.Cancer cell international · 2023Article
- Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.Journal of translational medicine · 2023Article
- Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment.Molecular cancer · 2023Review
- Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy.Stem cell research & therapy · 2022Review
- Screening and identification of HLA-A2-restricted neoepitopes for immunotherapy of non-microsatellite instability-high colorectal cancer.Science China. Life sciences · 2022Article
- Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma.Vaccines · 2021Article
- Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.Journal for immunotherapy of cancer · 2021Article
- The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure.Cells · 2021Review
- [Tumor vaccination-strategies and time points].Der Internist · 2021Review
- Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies.Gastroenterology · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePatient-specific (unique) tumour antigens, encoded by somatically mutated cancer genes, generate neoepitopes that are implicated in the induction of tumour-controlling T cell responses. Recent advancements in massive DNA sequencing combined with robust T cell epitope predictions have allowed their systematic identification in several malignancies.
designWe undertook the identification of unique neoepitopes in colorectal cancers (CRCs) by using high-throughput sequencing of cDNAs expressed by standard cancer cell cultures, and by related cancer stem/initiating cells (CSCs) cultures, coupled with a reverse immunology approach not requiring human leukocyte antigen (HLA) allele-specific epitope predictions.
resultsSeveral unique mutated antigens of CRC, shared by standard cancer and related CSC cultures, were identified by this strategy. CD8
conclusionsThese results provide a proof-of-concept approach for the identification of unique neoepitopes that are immunogenic in patients with CRC and can also target T cells against the most aggressive CSC component.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.